HORIZON USHER FOUNDATION
-
Non profit foundation
-
Born in January 2022
-
Raising awareness around Usher Syndrome & Retinitis Pigmentosa
-
Raising funds to help the medical research
HORIZON USHER FOUNDATION was created with the aim of raising funds to help the medical research of Usher Syndrome & Retinitis Pigmentosa caused by USH2A gene.
In an attempt to finally find the solution that could put an end to long years of research into a potential treatment to cure Retinitis Pigmentosa & Usher Syndrome, we decided to create Horizon Usher Foundation.
This foundation aims to help different research institutes by carrying out projects (for now more around sailing and fashion) and to seek great media coverage to give it a maximum visibility and raise as much funds as possible to give the possibility of creating new treatment protocols or new clinical trials.
OUR AMBITION
INFORM
&
RAISE AWARENESS
Bringing light and awareness to
Usher Syndrome & Retinitis Pigmentosa
Inform about recent medical advances
DEVELOP
MANY
PROJECTS
Mediate the disease through
projects and ideas we can develop
with brands or companies
Create unique content with a unique storytelling
ACT
&
HELP
Raising funds to help medical research
Help people with eyes diseases with the hope of healing them and restoring sight to those who have lost it
How do we help medical research ?
Our first and unforgettable project who launched Horizon Usher Foundation in the best possible way and who allowed us to raise funds and give a part to the institutes :
After M. Armani accepted the idea of our project, we worked a lot on the production to realize 2 chapters and 1 main movie in which we wanted to send a message : Retinitis Pigmentosa is still incurable and it's time to act.
The idea is of course to continue to grow, to realize in the near future other projects just as beautiful and unique as was the Horizon Project.
With our research teams, we are convinced that the call for donations, associated with strong media coverage of Horizon Usher Foundation through their various projects and the international reputation of the companies with which they collaborate, would be a great way to contribute together to the culmination of research projects on retinitis pigmentosa and to communicate on our recent advances that bring so much hope.
Serge Picaud
Director of Institut de la Vision